Evidence map›Paper›PMID 33344044›Full record

ArticleOncoimmunology2020

No impact of cancer and plague-relevant

Adriana Petrazzuolo, Julie Le Naour, Erika Vacchelli, Pascale Gaussem, Syrine Ellouze, Georges Jourdi, Eric Solary, Michaela Fontenay, David M Smadja, Guido Kroemer

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Adriana PetrazzuoloEquipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.
Julie Le NaourEquipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.ORCID 0000-0002-3749-2171
Erika VacchelliEquipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.ORCID 0000-0001-8010-0594
Pascale GaussemHematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux De Paris-Centre Université De Paris (APHP-CUP), Paris, France.
Syrine EllouzeBiological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France.
Georges JourdiInnovative Therapies in Haemostasis, INSERM, Université De Paris, Paris, France.
Eric SolaryFaculty of Medicine Kremlin Bicêtre, Université Paris Saclay, Paris, France.
Michaela FontenayBiological Hematology Department, Assistance Publique-Hôpitaux De Paris. Centre-Université De Paris, Paris, France.
David M SmadjaHematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux De Paris-Centre Université De Paris (APHP-CUP), Paris, France.
Guido KroemerEquipe Labellisée Par La Ligue Contre Le Cancer, Université De Paris, Sorbonne Université, INSERM U1138, Centre De Recherche Des Cordeliers, Paris, France.ORCID 0000-0002-9334-4405
Inserm · FRAcademy of Medical Sciences · GBAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Formyl peptide receptor 1 (FPR1) is a pattern-recognition receptor that detects bacterial as well as endogenous danger-associated molecular patterns to trigger innate immune responses by myeloid cells. A single nucleotide polymorphism, rs867228 (allelic frequency 19-20%), in the gene coding for FPR1 accelerates the manifestation of multiple carcinomas, likely due to reduced anticancer immunosurveillance secondary to a defect in antigen presentation by dendritic cells. Another polymorphism in

Indexed as

COVID-19FemaleHumansImmunity, InnateMaleMiddle AgedNeoplasmsPandemicsParisPlaguePolymorphism, Single NucleotideReceptors, Formyl PeptideSARS-CoV-2FPR1 protein, humanReceptors, Formyl PeptideImmunogeneticspathogen-associated molecular patternssars-CoV-2

Identifiers

PMID33344044
PMCPMC7734042
OpenAlexW3110773951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.